Phaeochromocytoma - Competitive landscape, 2026

DelveInsight’s, “Phaeochromocytoma - Competitive landscape, 2026,” report provides comprehensive insights about 3+ companies and 3+ drugs in Phaeochromocytoma Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Phaeochromocytoma: Understanding

Phaeochromocytoma: Overview

Pheochromocytoma is a rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla, with clinical manifestations primarily driven by excessive catecholamine secretion, particularly epinephrine, norepinephrine, and dopamine. These tumors may be benign or malignant and can occur sporadically or in association with hereditary syndromes such as neurofibromatosis type 1, multiple endocrine neoplasia type 2, and von Hippel–Lindau disease. Extra-adrenal tumors arising from chromaffin cells are termed paragangliomas and are considered alongside pheochromocytomas due to their similar characteristics. Most pheochromocytomas predominantly secrete epinephrine and/or norepinephrine, while sympathetic paragangliomas typically produce norepinephrine, with dopamine serving as a by-product. Although historically identified mainly during evaluations for secondary hypertension, pheochromocytomas are increasingly detected incidentally through abdominal imaging or genetic surveillance. Dopamine secretion has also been associated with an increased risk of malignancy, potentially due to its role in promoting angiogenesis.

Pheochromocytomas may occur sporadically or arise from inherited genetic factors, with germline mutations estimated to contribute to a substantial proportion of cases. Familial forms are commonly associated with genetic syndromes such as von Hippel–Lindau disease, multiple endocrine neoplasia type 2, and neurofibromatosis type 1, involving mutations in genes such as VHL, RET, and NF1. However, most cases occur sporadically without a known family history or identifiable underlying cause, although genetic susceptibility may still play a role. Risk is also higher among individuals with a family history of pheochromocytoma or paraganglioma, while factors such as intense physical activity, trauma, emotional stress, childbirth, anesthesia, and surgery may contribute to tumor manifestation or detection.

Catecholamine synthesis in chromaffin cells begins with the conversion of tyrosine to DOPA by tyrosine hydroxylase, followed sequentially by formation of dopamine, norepinephrine, and epinephrine through the actions of DOPA decarboxylase, dopamine ?-hydroxylase, and phenylethanolamine-N-methyltransferase, respectively. In pheochromocytoma, catecholamine release may be paroxysmal, continuous, or mixed, with predominantly continuous norepinephrine secretion contributing to sustained hypertension and episodic epinephrine release potentially causing tachyarrhythmias. Epinephrine and norepinephrine exert their effects through ?1, ?2, ?1, and ?2 adrenoceptors, with receptor selectivity varying by catecholamine. ?1-receptor activation in the heart increases cAMP-mediated signaling, enhancing cardiac contractility and conduction, while ?2-receptor stimulation promotes peripheral vasodilation; conversely, ?-receptor activation, particularly by norepinephrine, induces vasoconstriction and can increase blood pressure. Activation of presynaptic ?2 receptors inhibits further norepinephrine release, while glucocorticoids and thyroid hormones can modulate adrenoceptor expression and affinity.

Pheochromocytoma evaluation involves biochemical testing, imaging, and genetic assessment. Initial diagnosis relies on plasma-free or urinary-fractionated metanephrines, with plasma testing generally preferred for its diagnostic reliability; blood samples should ideally be collected after supine rest to reduce false positives. Following biochemical confirmation, CT of the abdomen and pelvis is typically used for tumor localization, with MRI as an alternative, while ¹?F-FDG PET may be used for suspected metastases and ¹²³I-MIBG imaging when MIBG-based therapy is considered. Given the substantial hereditary component, genetic testing is recommended for all patients, particularly those with younger age at diagnosis or bilateral tumors, focusing on genes such as VHL, RET, and NF1. Associated genetic alterations are broadly classified into pseudohypoxia, kinase-signaling, and Wnt-signaling pathways.

The definitive treatment for pheochromocytoma is surgical resection, preceded by ?- and ?-adrenergic blockade to reduce catecholamine-related complications. Minimally invasive adrenalectomy is preferred for most unilateral tumors, while open surgery may be used for large or invasive lesions. In bilateral or hereditary disease, cortical-sparing surgery can preserve adrenal function and reduce the need for lifelong steroid replacement. Preoperative management typically involves ?-blockade followed by ?-blockade, with calcium channel blockers as alternatives or adjuncts and adequate salt and fluid intake to correct volume depletion. Perioperative care focuses on preventing catecholamine surges and managing hemodynamic instability. For malignant or unresectable disease, options include cytoreductive surgery, chemotherapy, ¹³¹I-MIBG therapy, radiotherapy, and percutaneous ablation, while embolization may help stabilize severe catecholamine crises. Palliative treatment primarily aims to control symptoms and improve quality of life.

Report Highlights

• In September 2025, Cancer Research UK and Nxera Pharma announced that the first patient has been dosed in a Phase IIa clinical trial (NCT05944237)?evaluating Nxera’s investigational immunotherapy drug HTL0039732 (also known as NXE0039732) for advanced solid tumours. The decision to advance to Phase IIa follows the successful completion of the Phase 1 part of the trial, which identified a safe and well-tolerated dose of HTL0039732 – a novel EP4 antagonist – in combination with checkpoint inhibitor atezolizumab that achieves good engagement of the intended target EP4, without significantly engaging EP2.

• In May 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.

Phaeochromocytoma: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Merck

Merck, known as MSD outside the United States and Canada, is a science-driven biopharmaceutical company focused on developing innovative medicines and vaccines to improve health worldwide. With more than 130 years of experience, the company advances disease prevention and treatment across human and animal health while fostering an inclusive workforce and operating responsibly to support a safe, sustainable, and healthier future.

Product Description: Belzutifan

Belzutifan (WELIREG) is an oral, small-molecule HIF-2? inhibitor developed by Merck (MSD outside the US and Canada). It is used to treat locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL) in eligible adult and pediatric patients aged 12 years and older. By inhibiting HIF-2? signaling, belzutifan targets a key pathway involved in tumor growth, particularly in tumors associated with hypoxia-related signaling and genetic alterations. The PPGL indication was supported by the single-arm Phase II LITESPARK-015 trial, with objective response rate (ORR) as the primary endpoint.

Phaeochromocytoma: Company and Product Profiles (Pipeline Therapies)

2. Company Overview: Nxera Pharma

Nxera Pharma is a technology-driven biopharmaceutical company focused on discovering and developing innovative specialty medicines for patients with significant unmet needs in Japan and globally. The company has established an agile commercial platform in Japan to develop and commercialize innovative therapies, while its proprietary NxWave™ discovery platform supports a pipeline of more than 30 programs spanning discovery to late-stage clinical development, both independently and through partnerships with leading pharmaceutical and biotechnology companies. Its pipeline includes potential first- and best-in-class therapies targeting high-growth areas such as neurology and neuropsychiatry, metabolic diseases, and immunology and inflammation. Nxera employs approximately 400 people across key locations in Japan, the UK, Switzerland, and South Korea and is listed on the Tokyo Stock Exchange.

Product Description: HTL0039732

HTL0039732 is an oral small-molecule EP4 antagonist that blocks prostaglandin E2 (PGE2) signaling, which can suppress antitumor immune responses within the tumor microenvironment. By inhibiting EP4, HTL0039732 may enhance immune recognition and control of cancer cells, offering potential utility in tumors with limited responsiveness to existing immunotherapies. The trial is sponsored by Cancer Research UK ’s Centre for Drug Development while Nxera Pharma holds licensing rights to the trial results for further clinical development and commercialization. Currently, the drug is in Phase I/II stage of its development for the treatment of Phaeochromocytoma.

Further product details are provided in the report……..

?

Phaeochromocytoma Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: Phaeochromocytoma Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• Phaeochromocytoma Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Phaeochromocytoma Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Phaeochromocytoma drugs?
• How many Phaeochromocytoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Phaeochromocytoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Phaeochromocytoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Phaeochromocytoma and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

?

Key Players

• Merck
• Nxera Pharma

Key Products

• Belzutifan
• HTL0039732